French Biotech Develops a New Generation of Safer CAR-T Cells

Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of CAR-T cell therapies generated from both patient and donor cells.

Cellectis, a French biotech focused on developing CAR-T therapies from donor cells, has published a study in the journal Scientific Reports describing technological advances that could improve the safety of CAR-T cell therapies.

The technology, called CubiCAR, makes it easier for CAR-T cells to be detected and purified in the production process. Additionally, it allows CAR-T cells to be killed with the FDA-approved antibody Rituximab if the cells become toxic to non-cancerous tissue. Cellectis believes these properties will improve the safety and efficacy of future CAR-T treatments.


Cellectis is developing CubiCAR in partnership with US-biotech Allogene Therapeutics.

“We plan to evaluate this CubiCAR approach and other novel CAR T engineering developed in partnership with our colleagues at Cellectis across our extensive CAR T pipeline,” said Barbra Sasu, Chief Scientific Officer of Allogene.

Cellectis has been the first to test off-the-shelf CAR-T therapies, with results showing an 83% cancer remission rate. Additionally, the company raised $164M (€132M) earlier this year to continue the clinical development of its CAR-T treatments.

Nonetheless, Cellectis has also faced setbacks. For example, the FDA placed a hold on another one of Cellectis’ Phase I trials after the death of a patient that may have been caused by side effects of the CAR-T treatment. While the hold undoubtedly delayed the development of Cellectis’ CAR-T technology, it was lifted after several months.

Cellectis’ suicide-switch technology is competing with Poseida Therapeutics and Belliicum Pharmaceuticals. Poseida is developing a small molecule-based suicide switch. Bellicum is using two engineered proteins inside the CAR-T along with a small molecule that kick-starts the CAR-T cell’s suicide.

While CAR-T cell therapies have resulted in impressive cancer remission rates of up to 83%, the technology still has a long way to go before becoming a widely used treatment option. To live up to its full potential, biotechs focussed on CAR-T treatments will have to address issues such as toxicity and pricing, and develop the technology to target a broader range of cancers than it currently does.

Images by Meletios Verras/Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.